Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Clemens Messerschmidt - , Berlin Institute of Health at Charité (Author)
  • Benedikt Obermayer - , Berlin Institute of Health at Charité (Author)
  • Konrad Klinghammer - , Berlin Institute of Health at Charité (Author)
  • Sebastian Ochsenreither - , Berlin Institute of Health at Charité, German Cancer Research Center (DKFZ) (Author)
  • Denise Treue - , Berlin Institute of Health at Charité (Author)
  • Albrecht Stenzinger - , German Cancer Research Center (DKFZ), Heidelberg University  (Author)
  • Hanno Glimm - , National Center for Tumor Diseases Dresden, German Cancer Research Center, partner site Dresden, German Cancer Research Center (DKFZ), University Hospital Carl Gustav Carus Dresden, German Cancer Consortium (DKTK) Core Center Heidelberg (Author)
  • Stefan Fröhling - , German Cancer Research Center (DKFZ) (Author)
  • Thomas Kindler - , German Cancer Research Center (DKFZ), University Medical Center Mainz (Author)
  • Christian H. Brandts - , German Cancer Research Center (DKFZ), Goethe University Frankfurt a.M. (Author)
  • Klaus Schulze-Osthoff - , German Cancer Research Center (DKFZ), University of Tübingen (Author)
  • Wilko Weichert - , German Cancer Research Center (DKFZ), Technical University of Munich (Author)
  • Ingeborg Tinhofer - , German Cancer Research Center (DKFZ), Berlin Institute of Health at Charité (Author)
  • Frederick Klauschen - , German Cancer Research Center (DKFZ), Berlin Institute of Health at Charité (Author)
  • Ulrich Keilholz - , Berlin Institute of Health at Charité, German Cancer Research Center (DKFZ) (Author)
  • Dieter Beule - , Berlin Institute of Health at Charité, Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Damian T. Rieke - , Berlin Institute of Health at Charité (Author)

Abstract

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately reanalyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negative subgroup was identified, that showed higher T-cell inflammation and immune checkpoint expression, as well as expression of APOBEC3 genes. Mutations in immune-evasion pathways were also enriched in these tumors. Analysis of single-cell sequencing data identified expression of APOBEC3B and 3C genes in malignant cells. We identified an APOBEC-enriched subgroup of HPV-negative HNSCC with a distinct immunogenic phenotype, potentially mediating response to immunotherapy.

Details

Original languageEnglish
Pages (from-to)2293-2302
Number of pages10
JournalInternational journal of cancer
Volume147
Issue number8
Publication statusPublished - 15 Oct 2020
Peer-reviewedYes

External IDs

PubMed 32468570

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • APOBEC, head and neck cancer, immune checkpoint inhibition, mutational signature, tumor inflammation